
|Articles|May 17, 2022
Daily Medication Pearl: Danyelza (Naxitamab-gqgk)
Author(s)Saro Arakelians, PharmD
Naxitamab-gqgk (Danyelza) is for the treatment of pediatric and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
Advertisement
Medication Pearl of the Day: Danyelza (Naxitamab-gqgk)
Indication: Naxitamab-gqgk (Danyelza) is a GD2-binding monoclonal antibody indicated, in combination with granulocyte-macrophage colony-stimulating factor (GMCSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
Insight:
- Dosing:The recommended dosage of naxitamab-gqgk is 3 mg/kg/day (up to 150 mg/day), administered as an intravenous infusion after dilution on days 1, 3, and 5 of each treatment cycle.
- Dosage forms: Injection: 40 mg/10 mL (4 mg/mL) in a single-dose vial.
- Adverse events:The most common adverse reactions (≥25%) are infusion-related reaction, pain, tachycardia, vomiting, cough, nausea, diarrhea, decreased appetite, hypertension, fatigue, erythema multiforme, peripheral neuropathy, urticaria, pyrexia, headache, injection site reaction, edema, anxiety, localized edema, and irritability.
- Mechanism of action: Naxitamab-gqgk binds to the glycolipid GD2. GD2 is a disialoganglioside that is overexpressed on neuroblastoma cells and other cells of neuroectodermal origin, including the central nervous system and peripheral nerves. In vitro, naxitamab-gqgk was able to bind to cell surface GD2 and induce complement dependent cytotoxicity and antibody dependent cell-mediated cytotoxicity.
- Manufacturer: Y-mAbs Therapeutics
Source:
Advertisement
Related to this article

Extended INDIGO and FIREFLY-1 results presented at SNO 2026 put seizure burden during vorasidenib therapy and time off tovorafenib in pediatric low-grade glioma into focus.

The oral glucosylceramide synthase inhibitor crosses the blood-brain barrier, addressing a neurological component of the disease that enzyme replacement therapy cannot reach.

Health-system pharmacists confirm therapy matches stroke mechanism, screen for bleeding risk and drug interactions, and help patients transition to outpatient care.

Salia Farrokh, PharmD, MBA, describes how neurocritical care pharmacists have moved from answering questions to leading research, policy, and teaching, and why health systems must fund dedicated ICU pharmacists and protected time to sustain that growth.

With a mifepristone safety review due by March and Senate control shifting in January, the FDA faces an extended stretch without a permanent leader.

Higher doses of injectable semaglutide have been shown to cause greater weight loss than standard doses with a similar safety profile.
Advertisement
Advertisement
Trending on Pharmacy Times
1
mRNA-1283 Associated With Lower Risk of Medically Attended COVID-19 Than BNT162b2 in Older Veterans
2
Long-Acting HIV Injectables in Viremia and New Tenofovir-Free Oral Options
3
What Pharmacists Should Know About Transitioning Patients to Buprenorphine
4
Survodutide for Obesity and CV Risk: Liver, Lipids, and Beyond
5

